These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 884390)

  • 1. Possible mechanism of adverse reaction following levodopa plus benserazide treatment.
    Messiha FS
    Br J Pharmacol; 1977 May; 60(1):55-7. PubMed ID: 884390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of L-dopa alone and with benserazide on the spontaneous activity of striatal neurones in normal and 6-hydroxydopamine-lesioned rats.
    Chang WY; Webster RA
    Br J Pharmacol; 1997 May; 121(2):331-7. PubMed ID: 9154345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute non-haemolytic anemia after short administration of L Dopa plus Benserazide.
    Pezzoli G; Passerini D; Scarlato G; Radaelli F
    Ann Allergy; 1982 Jun; 48(6):362. PubMed ID: 7091780
    [No Abstract]   [Full Text] [Related]  

  • 5. The influence of benserazide on changes in monoamine oxidase activity in some rat tissues following treatment with L-DOPA.
    Callingham BA; Lyles GA
    J Auton Pharmacol; 1980 Nov; 1(1):9-16. PubMed ID: 7341636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
    Alachkar A; Brotchie JM; Jones OT
    Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
    Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK
    Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of L-dopa and an inhibitor of peripheral decarboxylation on glucose metabolism in brain.
    Tyce GM
    J Neurochem; 1976 Dec; 27(6):1397-403. PubMed ID: 1003214
    [No Abstract]   [Full Text] [Related]  

  • 9. ["Immune type" haemolysis in course of L. dopa-benserazide therapeutic (author's transl)].
    Conte P; Moulinier J; Reiffers J; Julien J
    Nouv Presse Med; 1979 Jan; 8(1):46-7. PubMed ID: 554063
    [No Abstract]   [Full Text] [Related]  

  • 10. [Long-term syndrome in the treatment of parkinsonism with L-dopa and decarboxylase an inhibitor].
    Chouza C; Romero S; Gomensoro JB
    Neurol Neurocir Psiquiatr; 1976; 17(4):255-68. PubMed ID: 828242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of deterioration in long-term treatment of parkinsonism with L-dopa plus decarboxylase inhibitor.
    Ludin HP; Bass-Verrey F
    J Neural Transm; 1976; 38(3-4):249-58. PubMed ID: 956811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration.
    Johnson RD; Ruthven CR; Goodwin BL; Sandler M
    J Neural Transm; 1976; 38(3-4):181-91. PubMed ID: 956809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benserazide dosing regimen affects the response to L-3,4-dihydroxyphenylalanine in the 6-hydroxydopamine-lesioned rat.
    Tayarani-Binazir KA; Jackson MJ; Strang I; Jairaj M; Rose S; Jenner P
    Behav Pharmacol; 2012 Apr; 23(2):126-33. PubMed ID: 22236652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Attempt at potentiation of the action of L-dopa on the secretion of growth hormone by benserazide, disulfiram and propranolol].
    Rochiccioli P; Enjaume P; Dutau G; Ribot C; Augier D
    Arch Fr Pediatr; 1976 Jan; 33(1):55-66. PubMed ID: 985031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
    Tsunekawa H; Takahata K; Okano M; Ishikawa T; Satoyoshi H; Nishimura T; Hoshino N; Muraoka S
    Behav Brain Res; 2018 Jul; 347():350-359. PubMed ID: 29526790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of VB6 on L-DOPA decarboxylase activity in the organs of rats given peripheral L-DOPA decarboxylase inhibitors (author's transl)].
    Yoshimine N; Kuzuya F; Mori K; Sakamoto N
    Nihon Ronen Igakkai Zasshi; 1978 Nov; 15(6):566-73. PubMed ID: 732010
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration.
    Pellegrini C; Antonioli L; Colucci R; Tirotta E; Gentile D; Ippolito C; Segnani C; Levandis G; Cerri S; Blandini F; Barocelli E; Ballabeni V; Bernardini N; Blandizzi C; Fornai M
    Neuropharmacology; 2017 Sep; 123():22-33. PubMed ID: 28526609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
    Huang L; Deng M; Zhang S; Fang Y; Li L
    Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of L-dopa combined with benserazide on hemodynamics and motor activity in hypoxic rats].
    Boismare F; Le Poncin M; Belliard JP; Hacpille L
    C R Seances Soc Biol Fil; 1975; 169(1):203-8. PubMed ID: 126730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of brain dopa-decarboxylase by RO 4-4602 infused ICV blocks alcohol drinking induced in rats by cyanamide.
    Miñano FJ; Myers RD
    Psychopharmacology (Berl); 1989; 98(2):176-82. PubMed ID: 2502790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.